ZOMETA® Patient Case Studies, Medical Profile and Statistics of a Prostate Cancer Patient

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Prostate Cancer

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETAŽ Prostate Cancer Patient Case Study Dieter

Dieter V.

Aged 61 years
Manages a department store
Coaches his grandson's football team

Page

1 2 3

Dieter is not alone

65% to 75% of patients with advanced prostate cancer will develop bone metastases¹
49% of patients with prostate cancer and bone metastases will experience a skeletal-related event (SRE) without treatment²
SREs are generally defined as pathologic fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcemia³

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.